EP0674528A4 - Cyclodextrin and polymer based drug delivery system. - Google Patents

Cyclodextrin and polymer based drug delivery system.

Info

Publication number
EP0674528A4
EP0674528A4 EP94902482A EP94902482A EP0674528A4 EP 0674528 A4 EP0674528 A4 EP 0674528A4 EP 94902482 A EP94902482 A EP 94902482A EP 94902482 A EP94902482 A EP 94902482A EP 0674528 A4 EP0674528 A4 EP 0674528A4
Authority
EP
European Patent Office
Prior art keywords
cyclodextrin
delivery system
drug delivery
polymer based
based drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94902482A
Other languages
German (de)
French (fr)
Other versions
EP0674528A1 (en
Inventor
Sheng-Wan Tsao
Lyle M Bowman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Inc
Original Assignee
Insite Vision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/984,445 external-priority patent/US5332582A/en
Application filed by Insite Vision Inc filed Critical Insite Vision Inc
Publication of EP0674528A1 publication Critical patent/EP0674528A1/en
Publication of EP0674528A4 publication Critical patent/EP0674528A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP94902482A 1992-12-02 1993-12-01 Cyclodextrin and polymer based drug delivery system. Withdrawn EP0674528A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US07/984,445 US5332582A (en) 1990-06-12 1992-12-02 Stabilization of aminosteroids for topical ophthalmic and other applications
US984445 1992-12-02
US15516793A 1993-11-19 1993-11-19
US155167 1993-11-19
PCT/US1993/011651 WO1994012217A1 (en) 1992-12-02 1993-12-01 Cyclodextrin and polymer based drug delivery system

Publications (2)

Publication Number Publication Date
EP0674528A1 EP0674528A1 (en) 1995-10-04
EP0674528A4 true EP0674528A4 (en) 1996-06-26

Family

ID=26852057

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94902482A Withdrawn EP0674528A4 (en) 1992-12-02 1993-12-01 Cyclodextrin and polymer based drug delivery system.

Country Status (6)

Country Link
EP (1) EP0674528A4 (en)
JP (1) JPH08503951A (en)
CN (1) CN1103316A (en)
AU (1) AU672862B2 (en)
CA (1) CA2150554A1 (en)
WO (1) WO1994012217A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW434023B (en) * 1995-09-18 2001-05-16 Novartis Ag Preserved ophthalmic composition
JP3940209B2 (en) 1996-11-14 2007-07-04 株式会社資生堂 Solubilized cosmetics
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6656456B2 (en) 1998-11-23 2003-12-02 The Procter & Gamble Company Skin deodorizing compositions
WO2000030599A1 (en) * 1998-11-23 2000-06-02 The Procter & Gamble Company Skin deodorizing and sanitizing compositions
CA2373237A1 (en) * 2000-03-10 2001-09-20 Insite Vision Incorporated Methods and compositions for treating and preventing posterior segment ophthalmic disorders
AU2001259298A1 (en) 2000-05-02 2001-11-12 Advanced Medicine, Inc. Polyacid glycopeptide derivatives
SI1278549T1 (en) 2000-05-02 2009-04-30 Theravance Inc Composition containing a cyclodextrin and a glycopeptide antibiotic
US6828299B2 (en) 2000-06-22 2004-12-07 Theravance, Inc. Polyhydroxy glycopeptide derivatives
ES2302733T3 (en) 2000-06-22 2008-08-01 Theravance, Inc. CARBOXI-SACARIDS DERIVATIVES OF GLUCOPEPTIDE.
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
UA75083C2 (en) 2000-06-22 2006-03-15 Тераванс, Інк. Derivatives of glycopeptidephosphonates
AU2001288120A1 (en) * 2000-09-26 2002-04-08 Kyorin Pharmaceutical Co. Ltd. Liquid prednisolone sodium phosphate preparation
CA2445606A1 (en) * 2001-05-11 2002-11-21 Pacific Pharmaceuticals Limited Taste masking pharmaceutical composition
WO2004091630A1 (en) * 2003-04-18 2004-10-28 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2006040839A1 (en) * 2004-10-15 2006-04-20 Advanced Medicine Research Institute Eye drops and kit for treatment of eye disease
JP2007177149A (en) * 2005-12-28 2007-07-12 Shield Lab:Kk Inclusion compound of thioctic acid or dihydrolipoic acid with branched cyclodextrin
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
EP2234614B1 (en) 2007-12-21 2012-10-17 AOP Orphan Pharmaceuticals AG Pharmaceutical composition for parenteral administration of an ultrashort acting beta-adrenoreceptor antagonist
US10980818B2 (en) 2009-03-06 2021-04-20 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US10201548B2 (en) 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
EP3520749A1 (en) 2010-10-15 2019-08-07 Clearside Biomedical, Inc. Device for ocular access
US20150258120A1 (en) 2012-11-08 2015-09-17 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
US20150374832A1 (en) * 2013-02-12 2015-12-31 Ys Pharm Tech Epinephrine formulations for medicinal products
JP6379183B2 (en) 2013-05-03 2018-08-22 クリアサイド バイオメディカル,インコーポレイテッド Apparatus and method for ocular injection
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
CN103990137A (en) * 2014-04-30 2014-08-20 福建融和药业有限公司 Slow-release agent of mucoadhesive polymer eye medicines
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
JP2019514581A (en) 2016-05-02 2019-06-06 クリアサイド バイオメディカル,インコーポレイテッド Systems and methods for ocular drug delivery
CN110177527B (en) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 Device and method for adjusting insertion depth of needle for medicament delivery
CN109136177B (en) * 2018-08-03 2021-09-17 湖南大学 Dexamethasone slow-release system, osteogenic differentiation inducing liquid and application
RU2740287C1 (en) * 2019-08-30 2021-01-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) 3d-matrix structure for drug delivery
CN115380899A (en) * 2022-08-30 2022-11-25 陕西科技大学 Gel type humic acid slow release pesticide and preparation method thereof
WO2024097388A1 (en) * 2022-11-03 2024-05-10 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for monitoring fatty acid metabolism

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300526A2 (en) * 1987-07-01 1989-01-25 Janssen Pharmaceutica N.V. Antiviral pharmaceutical compositions containing cyclodextrins
EP0399716A1 (en) * 1989-05-24 1990-11-28 Innovet, Inc. Hypoallergenic steroidal anesthetic/hypnotic compositions
EP0463653A1 (en) * 1990-06-07 1992-01-02 PHARMACIA S.p.A. Galenic formulations containing cyclodextrins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300526A2 (en) * 1987-07-01 1989-01-25 Janssen Pharmaceutica N.V. Antiviral pharmaceutical compositions containing cyclodextrins
EP0399716A1 (en) * 1989-05-24 1990-11-28 Innovet, Inc. Hypoallergenic steroidal anesthetic/hypnotic compositions
EP0463653A1 (en) * 1990-06-07 1992-01-02 PHARMACIA S.p.A. Galenic formulations containing cyclodextrins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9412217A1 *

Also Published As

Publication number Publication date
JPH08503951A (en) 1996-04-30
AU5684194A (en) 1994-06-22
EP0674528A1 (en) 1995-10-04
AU672862B2 (en) 1996-10-17
CN1103316A (en) 1995-06-07
WO1994012217A1 (en) 1994-06-09
CA2150554A1 (en) 1994-06-09

Similar Documents

Publication Publication Date Title
EP0674528A4 (en) Cyclodextrin and polymer based drug delivery system.
US5525634B1 (en) Colonic drug delivery system
EP0662851A4 (en) Drug delivery system.
AU664807B2 (en) Drug delivery system
AU3127697A (en) Intravenous catheter and delivery system
AU8935591A (en) Drug delivery system and method
IL117706A0 (en) Powdered drug storage and delivery system
ZA988203B (en) Aerosol medication delivery apparatus and system.
AU3204995A (en) Closed drug delivery system
EP0643976A3 (en) Cardioplegia delivery system.
AU9617698A (en) Polymeric systems for drug delivery and uses thereof
EP0647133A4 (en) Compositions and methods for enhanced drug delivery.
ZA967502B (en) Medicament delivery device.
AU7676894A (en) Convection-enhanced drug delivery
AU3290397A (en) Gastric-retentive oral controlled drug delivery system with enhanced retention properties
ZA965931B (en) Transcorneal drug delivery system.
AU4406793A (en) Water-soluble polymeric carriers for drug delivery
EP0671165A3 (en) Collagen-based injectable drug delivery system and its use.
AU1719800A (en) Drug delivery systems and methods
EP0648239A4 (en) Biocompatible polymer conjugates.
AU4468197A (en) Hyaluronic drug delivery system
AU660290B2 (en) Multiple drug delivery system
AU3481497A (en) Chitosan drug delivery system
GB9325330D0 (en) Fluorocyclodextrin drug delivery system
EP0636363A3 (en) Drug delivery system.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950529

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19960509

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980813